Status: Not yet recruiting
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection
This study is designed to assess safety, pharmacokinetics, and efficacy ABI-6250 in participants with Chronic Hepatitis D Virus Infection.
Participants needed: 80
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Assembly BiosciencesUpdated: Aug 13, 2026Locations: 22
Eligibility criteria
Participant has a body mass index ≥18.0 and <35.0 kg/m2 at Screening [+2]
Participant has a current coinfection with acute hepatitis A virus (HAV), hepati... [+3]